bluebird bio (NASDAQ:BLUE) Receives “Buy” Rating from Cowen

bluebird bio (NASDAQ:BLUE)‘s stock had its “buy” rating restated by research analysts at Cowen in a research report issued on Friday, AnalystRatings.com reports.

Several other brokerages have also recently issued reports on BLUE. Morgan Stanley set a $100.00 price target on bluebird bio and gave the company a “hold” rating in a research report on Friday, November 1st. Evercore ISI cut bluebird bio from an “outperform” rating to an “in-line” rating in a research report on Wednesday, November 27th. Leerink Swann raised bluebird bio from a “market perform” rating to an “outperform” rating and set a $119.00 price objective for the company in a research report on Tuesday, November 26th. Svb Leerink upgraded bluebird bio from a “market perform” rating to an “outperform” rating and set a $119.00 target price on the stock in a research note on Tuesday, November 26th. Finally, Stifel Nicolaus set a $96.00 target price on bluebird bio and gave the company a “hold” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $139.86.

BLUE stock traded down $1.23 on Friday, hitting $79.42. The company’s stock had a trading volume of 1,008,825 shares, compared to its average volume of 657,691. The stock has a market cap of $4.48 billion, a price-to-earnings ratio of -7.44 and a beta of 2.16. The firm has a 50 day moving average of $80.36 and a two-hundred day moving average of $107.05. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.12. bluebird bio has a 1 year low of $71.42 and a 1 year high of $163.43.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($3.73) EPS for the quarter, missing analysts’ consensus estimates of ($3.54) by ($0.19). bluebird bio had a negative net margin of 1,326.56% and a negative return on equity of 42.29%. The business had revenue of $8.91 million during the quarter, compared to analyst estimates of $12.47 million. During the same quarter in the prior year, the firm posted ($2.73) earnings per share. The company’s revenue for the quarter was down 22.7% compared to the same quarter last year. As a group, equities analysts forecast that bluebird bio will post -14.06 EPS for the current fiscal year.

In related news, insider David Davidson sold 2,060 shares of bluebird bio stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $100.16, for a total value of $206,329.60. Following the sale, the insider now directly owns 34,616 shares in the company, valued at $3,467,138.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold a total of 2,560 shares of company stock valued at $249,085 over the last three months. Insiders own 3.00% of the company’s stock.

Several hedge funds have recently bought and sold shares of BLUE. Capital Investment Advisory Services LLC grew its holdings in shares of bluebird bio by 100.0% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 100 shares during the period. CSat Investment Advisory L.P. acquired a new stake in bluebird bio in the second quarter valued at $31,000. Trust Co. of Vermont grew its holdings in bluebird bio by 40.6% in the second quarter. Trust Co. of Vermont now owns 253 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 73 shares during the last quarter. Rational Advisors LLC increased its position in shares of bluebird bio by 532.3% in the third quarter. Rational Advisors LLC now owns 392 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 330 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of bluebird bio in the second quarter valued at $47,000.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Featured Article: Liquidity

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.